News

Get the latest from Biologics

We invite you to learn more about our work. Check out our organization’s recent news, and browse our press releases to see what we’ve been doing. You can also check out upcoming events in which we’ll be participating or read more about our how we give back to our community.

Biologics, Inc. reports exceptional patient survey results

CARY, NC — February 17, 2016 —Biologics, Inc., an oncology pharmacy services company, is pleased to announce the results of its 2015 third-party patient survey. In 2015, 97 percent of pharmacy patients who responded to the survey agreed that their overall experience with Biologics was exceptional. Ninety-seven percent of patients reported their medication was delivered… Read More

Biologics Team Secures Over $49 Million in Copay Assistance for Cancer Patients in 2015

CARY, NC — February 9, 2016 — Biologics, Inc. announced today that its team has helped secure over $49 million in copay card and foundation assistance for patients in need of oral oncology medication. As a result of the high cost associated with cancer therapy, over twenty percent of Biologics’ patients request financial assistance to… Read More

Biologics, Inc. Announces New Oncology Partnership

CARY, NC — February 1, 2016 — Biologics, Inc. has been selected by TESARO, Inc. as the exclusive specialty pharmacy provider for VARUBI™ (rolapitant), the company is pleased to announce. VARUBI was approved by the U.S. Food and Drug Administration on September 1, 2015, in combination with other antiemetic agents in adults for the prevention… Read More

Biologics’ Community Service Program Reaches New Milestones in 2015

At Biologics, our commitment to serving others extends beyond our patients and our clients to the community we call home. Through our ECHO (Employees Caring and Helping Others) Program, employees have eagerly donated time and money this year to various organizations, continuously striving to make a positive impact on those around us. As 2015 comes… Read More

NINLARO™ (ixazomib) Approved for Patients with Multiple Myeloma, available at Biologics, Inc.

CARY, NC — December 2, 2015 — Biologics, Inc., is pleased to announce that it has been selected by Takeda Oncology as a specialty pharmacy provider for Ninlaro (ixazomib). Ninlaro was granted priority review and orphan drug status, and approved by the U.S. Food and Drug Administration on November 20, 2015, in combination with lenalidomid… Read More

PORTRAZZA™ (necitumumab) approved as first-line therapy for metastatic, squamous non-small cell lung cancer, available at Biologics, Inc.

CARY, NC — November 30, 2015 — Biologics, Inc., is pleased to announce that it has been selected by Lilly Oncology as the exclusive specialty pharmacy provider for PORTRAZZA™ (necitumumab). In addition to accessing the drug via specialty distribution, Eli Lilly will offer physicians and healthcare practices the opportunity to order PORTRAZZA™ through Biologics’ specialty… Read More

Tagrisso™ (osimertinib) approved for advanced lung cancer, available immediately at Biologics, Inc.

CARY, NC — November 16, 2015 — Biologics, Inc. is pleased to announce that it has been selected by AstraZeneca as a specialty pharmacy provider for Tagrisso (osimertinib). Tagrisso was designated as a Breakthrough Therapy by the U.S. Food and Drug Administration, and was approved on November 13, 2015, for the treatment of advanced lung… Read More

COTELLIC™ (cobimetinib) approved in combination for BRAF V600+ metastatic melanoma, available at Biologics, Inc.

CARY, NC — November 16, 2015 — Biologics, Inc., is pleased to announce that it has been selected by Genentech as a specialty pharmacy provider for COTELLIC (cobimetinib). COTELLIC was granted priority review, and approved by the U.S. Food and Drug Administration on November 10, 2015, to be used in combination with ZELBORAF (vemurafenib) for… Read More

LONSURF® (trifluridine and tipiracil) approved for refractory metastatic colorectal cancer, available at Biologics, Inc.

CARY, NC — October 7, 2015 — Biologics, Inc., is pleased to announce that it has been selected by Taiho Oncology, Inc. as a specialty pharmacy provider for LONSURF® (trifluridine and tipiracil). LONSURF was approved by the U.S. Food and Drug Administration on September 22, 2015, for the treatment of patients with metastatic colorectal cancer… Read More

Biologics, Inc. Selected to Dispense AstraZeneca’s IRESSA® (gefitinib)

CARY, NC — August 13, 2015 — Biologics, Inc., is pleased to announce that it has been selected by AstraZeneca as a specialty pharmacy provider for IRESSA® (gefitinib). IRESSA® was approved by the U.S. Food and Drug Administration on July 13, 2015, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC)… Read More